Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Sangamo Therapeutics (SGMO) Misses Q1 EPS by 2c, Revenues Beat
May 4, 2021 5:24 PM EDTSangamo Therapeutics (NASDAQ: SGMO) reported Q1 EPS of ($0.32), $0.02 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $26.28 million versus the consensus estimate of $23.98 million.
This quarter, we have continued our focus on advancing our lead programs through clinical execution, regulatory... More
